Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Want to cut your energy bills? Here’s how five experts are doing it 
NEW YORK, Feb. 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PixarBio Corporation (OTC MKTS:PXRB) securities (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/pixarbio-corporation. There is no cost or obligation to you.
According to the complaint, PixarBio made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.
If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/pixarbio-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
